09-07-06

SEP 0 6 2006

PTO/SB/21 (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application Number	10/517,695-Conf. #1897
TRANSMITTAL FORM		Filing Date	December 13, 2004
		First Named Inventor	Mark J. EVANS
(to be used for all correspondence after initial I	filing)	Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	3	Attorney Docket Number	0036119.00159US4/AM100886US

_	EN	ICLOSURES (Check all	that app	ly)	
Fee Transmittal Form Drawi		Drawing(s)		After Allowance Communication to TC	
Fee .	Attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendme	nt/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After	Final	Petition to Convert to a Provisional Application		Proprietary Information	
Affid	avits/declaration(s)	Power of Attorney, Revocat Change of Correspondence		Status Letter	
Extension	of Time Request	Terminal Disclaimer		X Other Enclosure(s) (please Identify below):	
Express Al	bandonment Request	Request for Refund		Return Receipt Postcard	
X Supplemental Information Disclosure Statement		CD, Number of CD(s)			
Certified Copy of Priority Document(s)		Landscape Table or	CD		
Reply to Missing Parts/ Incomplete Application		Remarks			
Reply to Missing Parts under 37 CFR 1.52 or 1.53					
	SIGNATU	JRE OF APPLICANT, ATTO	RNEY, OR	AGENT	
WILMER CUTLER PICKERING HALE AND DORR LLP					
Signature	ature Colller Superko				
Printed name	Colleen Superko				
Date	September 6, 2006		Reg. No.	39,850	

Express Mail Label No. EV 507047142 US Dated: September 6, 2006

Docket No.: 0036119.00159US4/AM100886US (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Mark J. EVANS et al.

Confirmation No.:

1897

Application No.:

10/517,695

Art Unit:

Not Yet Assigned

Filed:

December 13, 2004

Examiner:

Not Yet Assigned

Title:

INHIBITORS OF INFLAMMATORY GENE ACTIVITY AND

CHOLESTEROL BIOSYNTHESIS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Applicants state that each item of information contained in the Information Disclosure Statement was first cited in a communication (copy enclosed) from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: September 6, 2006

Colleen Superko

Registration No.: 39,850 Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109 (617) 526-6000 (telephone) (617) 526-5000 (facsimile)

US1DOCS 5824527v1



PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
				Application Number	10/517,695-Conf. #1897
l IN	IFORMATION	I DI	SCLOSURE	Filing Date	December 13, 2004
S	STATEMENT BY APPLICANT			First Named Inventor	Mark J. EVANS
				Art Unit	Not Yet Assigned
	(Use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	0036119.00159US4/AM100886US

			U.S. PA	TENT DOCUMENTS	
Examiner	634	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	AA*	US-5,728,548	03-17-1998	Bowman	

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.'	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	Ľ
	BA	WO-01/53312 A	07-26-2001	HYSEQ, INC.		
	BB	WO-02/32410 A	04-25-2002	IMPERIAL COLLEGE		
	İ			INNOVATIONS LIMITED		L_
	ВС	WO-00/71697A (see Ref. CC)	11-30-2000	SANKYO COMPANY		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	KIM, et al., "The Orphan Nuclear Receptor of Small Heterodimer Partner as a Novel	
		Coregulator of Nuclear Factor-kB in Oxidized Low Density Lipoprotein-Treated Macrophage Cell Line RAW 264.7", Journal of Biological Chemistry, 276(36):33736-33740 (2001)	
	СВ	MORI, et al., "Activation of Intercellular Adhesion Molecule 1 Expression by Helicobacter Pylori is Regulated by NF-κB in Gastric Epithelial Cancer Cells", Infection and Immunity, 68(4):1806-1814 (2000)	
	CC	DATABASE WPI, Week 2001, AN 2001-11208, XP-002389087 (See Ref. BC)	
	CD	BERGHE, et al., "Dissociated Glucocorticoids with Anti-Inflammatory Potential Repress Interleukin-6 Gene Expression by a Nuclear Factor-κB-Dependent Mechanism", Molecular Pharmacology, 56(4):797-806 (1999)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.



Application No. (if known): 10/517,695

Attorney Docket No.: 0036119.00159US4

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 507047142 US in an envelope addressed to:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on <u>6 Sept 2006</u>
Date

Stephanie R. Douglas

Typed or printed name of person signing Certificate

(617) 526-6000

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal Letter
Supplemental IDS
PTO/SB/08 citing 8 references
Copies of 7 references